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The Australian and New Zealand living stroke management guidelines provide timely,
evidence-based updates to recommendations

C

ontinued growth in the number of published
clinical studies has necessitated changes to
the way evidence-based resources such as
clinical guidelines are developed and updated. The
Australian and New Zealand Clinical Guidelines for
Stroke Management (https://informme.org.au/guide
lines/clinical-guidelines-for-stroke-management) are
based on continual evidence surveillance and timely
updates to recommendations as new research is
published. In this article, we outline the main updates
to recommendations since the guidelines moved into
a living mode in 2018, and discuss key challenges and
benefits of living guidelines.

Background
Stroke is a leading cause of adult disability in
Australia, with an estimated 27 428 incident strokes
occurring each year, or one every 19 minutes.1
Compared with urban areas, the incidence of stroke
is 17% higher in rural communities, where access to
specialist stroke care is less likely.1 This makes the
need for easily accessible, up-to-date, evidenced-based
clinical practice guidelines for stroke care essential.
The first Australian clinical guidelines for stroke were
published in 2003 (acute) and 2005 (post-acute). These
were updated in 2007, 2010 and most recently in 2017
following traditional methods, including endorsement
by the National Health and Medical Research Council
(NHMRC). In 2017, the guidelines moved from being
published in a static (pdf) format, to being published
online using the Making GRADE the Irresistible Choice
(MAGICapp) platform (https://magicevidence.org).2
Traditional cycles of guideline updates which
involve recommendations based on the best
available evidence at the time of publication are
problematic because new evidence can mean that
recommendations quickly become outdated. In
2018, the Stroke Foundation and Cochrane Australia
were awarded funding to test a model of living
guidelines for stroke management. These were
the first Australian living clinical guidelines and
are the first and only living stroke guidelines
worldwide. Subsequent living guidelines include
those for diabetes, 3 maternal and perinatal health,4
and COVID-19.5 The stroke guidelines are published
online at https://inform me.org.au/guidel ines/clini
cal-guidel ines-for-stroke-management, to guide day-
to-day stroke care in Australia and New Zealand.

Development
The 2017 update of the static stroke guidelines
consisted of 392 individual recommendations

including practice points across eight chapters
addressing 89 topics. Each topic was structured into
a PICO (patient, intervention, comparator, outcome)
format to address an aspect of care, for example, the
use of cholesterol-lowering therapy for secondary
prevention of stroke. The living stroke guidelines
project commenced in July 2018. The structures in place
for the 2017 static guidelines update were adapted
and expanded to fit living guidelines methods. A full
description of the methods is published elsewhere.6
In brief, each month the results of published new
studies are reviewed by the project team. Where
new evidence is deemed to potentially impact
one or more recommendations, the project team
works with clinical experts to update evidence-
to-decision frameworks (benefits and harms and
certainty of evidence component) using the Grading
of Recommendations, Assessment, Development
and Evaluation (GRADE) method (https://gdt.grade
pro.org/app/handbook/handbook.html), and draft
changes to recommendations and background text.
Draft changes go through a rigorous review process,
culminating in submission to the NHMRC for
approval (median time from initiation to submission
is about 6 months). Clinical indicators collected as part
of the National Stroke Audit and the Australian Stroke
Clinical Registry are monitored over time to evaluate
adherence to aspects of the guidelines.
The living clinical guidelines for stroke are developed
in accordance with NHMRC standards, including the
use of the GRADE method for recommendations. The
MAGICapp platform presents the recommendations
and related information in a multilayered, transparent
format. MAGICapp allows users to review all previous
versions of each recommendation for full transparency.
Any new or updated recommendations are flagged as
such within the platform for a period of 6–12 months.
A summary of updates is also maintained online
(https://informme.org.au/guidelines/living-guide
lines-updates).

Recommendations
Since the 2017 update to the static guideline, a total
of 35 new or updated recommendations have been
made. Just under half (16) of the changes are new
recommendations (five strong, 10 weak, and one
practice point), with updates to 19 recommendations
(12 without change to the direction or grade of
recommendation, six upgraded strength, and one
downgraded strength [from weak recommendation for
to weak recommendation against]). New and updated
strong recommendations are presented in the Box. All
new and updated recommendations are reported in
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the Supporting Information and are described in brief
below.
Acute medical and surgical management
The first living guideline recommendation, developed
after the 2017 update but before the start of the
funded living guidelines project, extended the time
window for endovascular clot retrieval to 24 hours for
specific clinical presentations.11 Additionally, based
on results from new studies,12-14 the recommended
time window for safe administration of alteplase
has been extended to 9 hours post-stroke and a new
recommendation made about safe use of alteplase for
stroke of unknown onset time. Both recommendations
are based on favourable perfusion imaging. Two new
recommendations have been made for the use of
tenecteplase as an alternative to alteplase within 4.5
hours of stroke onset15 or for large vessel occlusions.16
Ticagrelor in combination with aspirin commenced
within 24 hours of symptom onset and continued for
the first 30 days may now be used for acute antiplatelet
therapy for people with minor ischaemic stroke or
transient ischaemic attack,17 although this should be
considered secondary to a strong recommendation
for aspirin plus clopidogrel for the first 21 days. The
recommendation for oxygen therapy has been updated
to include a specific threshold (92% blood oxygen
saturation on room air), above which routine use of
supplemental oxygen therapy is not recommended.18
There is a new recommendation for the use of
telestroke services to assist in patient assessment and
decision making for the use of thrombolysis and/or
endovascular clot retrieval for people presenting to
hospitals where medical specialist services are not
available.19,20 Finally, there is a new recommendation
that clarifies that patients not receiving nasogastic
feeding do not require head elevation and may be
managed in any position.21
Secondary prevention

Rehabilitation
The most significant updated recommendation
pertains to the use of selective serotonin reuptake
inhibitors (SSRIs) to reduce disability after stroke. New

Managing complications
Due to an increase in the number of published high
quality, albeit small trials, it is now recommended that
acupuncture may be considered for the management of
shoulder pain after stroke.30 Minor changes have also
been made in preventing or managing swelling in the
arms or legs.

Discussion
Major updates to the guidelines over the past four
years have occurred, ensuring the recommendations
are current. Importantly, there have been no cases in
which a recommendation for an intervention has been
downgraded from a strong to a weak recommendation.
Furthermore, no recommendation has been changed
multiple times. Important new recommendations
have been made regarding lifesaving therapy such
as extension of the time window for endovascular
clot retrieval and the administration of alteplase for
thrombolysis.
The key benefit of living guidelines is the ability
to rapidly update recommendations in response to
new evidence. As a case example, results from the
EXTEND trial demonstrating the safety and efficacy of
thrombolysis up to 9 hours after stroke were published
in May 2019,12 followed soon after by a systematic
review and individual patient data meta-analysis.13
By November 2019, our updated recommendation had
completed the full development, review and public
consultation process and was endorsed by the NHMRC
and disseminated to key end-user organisations; a total
time of less than six months.
While it is hard to estimate the direct and definitive
impact of rapid guideline updates, based on trial
outcomes and reported patient numbers, we estimate
that about 320 Australians each year may be saved
from premature death or disability following a
severe stroke based on the updated recommendations
for endovascular clot retrieval from 6–24 hours
after symptom onset (unpublished data). Rapid
guideline updates as part of a living model are
almost certain to have played a significant role by
expediting local and state-w ide system changes.
Further work to quantify the impact, including the
potential economic impact and return-on-i nvestment,
of the living guidelines compared with traditional
guideline updates is planned. Since 2007, we have
had national, standardised systems of monitoring
adherence to the clinical guideline recommendations
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Several recommendations have been updated
regarding secondary prevention. The first specifies
a target of < 1.8 mmol/L for low density lipoprotein
levels for people with ischaemic stroke.22 The
recommendation for management of patent foramen
ovale now specifies that where this is considered the
likely cause of stroke, percutaneous closure should
occur.23 People who were taking antiplatelet therapy
before experiencing an intracerebral haemorrhage may
be safely recommenced, although the optimal timing
for this is not clear.24 Left atrial appendage occlusion
may be considered for the management of atrial
fibrillation if there is a genuine contraindication to
anticoagulation.25 Non-pharmacological interventions
to reduce stroke risk factors include exercise training
as well as individual support and counselling, and the
final new recommendation suggests that people with
stroke should follow a Mediterranean style diet.26

large trials27,28 found SSRIs did not reduce disability
and were associated with a small risk of harm, and
therefore are no longer recommended for routine use
in this context but may still be relevant specifically
to prevent or treat depression. The recommendations
for management of motor weakness and difficulty
standing have been updated. These updates include
greater specificity in the types of training modalities
that are recommended. Finally, new recommendations
for specific interventions to improve memory function,
and for the use of telehealth as an alternative mode of
rehabilitation service delivery29 have been made.
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Summary of new and updated strong recommendations
Specific recommendations

New or updated

Summary of change

Acute medical and
surgical management
Thrombolysis

For patients with potentially disabling ischaemic
stroke who meet perfusion mismatch criteria in
addition to standard clinical criteria, intravenous
alteplase (0.9 mg/kg, maximum 90 mg) should
be administered up to 9 hours after the time the
patient was last known to be well, or from the
midpoint of sleep for patients who wake with
stroke symptoms, unless immediate endovascular
thrombectomy is planned

New

Extends the time window
recommended for thrombolysis
treatment up to 9 hours after time
of stroke where imaging findings
suggest benefit

For patients with potentially disabling ischaemic
stroke due to large vessel occlusion who meet
specific eligibility criteria, intravenous tenecteplase
(0.25 mg/kg, maximum 25 mg) or alteplase (0.9 mg/
kg, maximum of 90 mg) should be administered
up to 4.5 hours after the time the patient was last
known to be well

New

Addition of a new recommended
antithrombotic agent (tenecteplase)

Neurointervention

For patients with ischaemic stroke caused by a
large vessel occlusion in the internal carotid artery,
proximal middle cerebral artery (M1 segment), or
with tandem occlusion of both the cervical carotid
and intracranial large arteries, endovascular
thrombectomy should be undertaken when the
procedure can be commenced between 6 and 24
hours after they were last known to be well if
clinical and computed tomography perfusion or
magnetic resonance imaging features indicate the
presence of salvageable brain tissue

New

Extends the time window for
endovascular clot retrieval to 24
hours, in specific circumstances

Acute antithrombotic
therapy

Aspirin plus clopidogrel should be commenced
within 24 hours and used in the short term (first
3 weeks) in patients with minor ischaemic stroke
or high risk transient ischaemic attack to prevent
stroke recurrence

Updated

New evidence of benefit of dual
antiplatelet therapy to prevent
secondary stroke7

Acute telehealth
services

In hospitals without onsite 24/7 stroke medical
specialist availability, telestroke systems should
be used to assist in patient assessment and
decision making regarding acute thrombolytic
therapy and possible transfer for endovascular
therapy. This system should include the ability for
stroke medical specialists to access remote brain
imaging scans and preferably include the use of
videoconferencing facilities or, if not possible,
ensure that the diagnosis and management
discussions between local clinicians, families and
patients occur via a telephone consultation

New

This recommendation aims to ensure
all Australians have access to best
practice acute therapies after stroke,
regardless of where they live

Cholesterol lowering
therapy

In patients with ischaemic stroke, cholesterol
lowering therapy should target low density
lipoprotein cholesterol < 1.8 mmol/L for secondary
prevention of atherosclerotic cardiovascular
disease

New

New trial evidence shows that more
intensive lowering of low density
lipoprotein levels reduces recurrent
cardiovascular events 8

Patent foramen ovale
management

In patients with ischaemic stroke aged < 60 years
in whom a patent foramen ovale is considered the
likely cause of stroke after thorough exclusion
of other aetiologies, percutaneous closure of the
patent foramen ovale is recommended

Updated

Two new trials, long term follow-up
of a previous trial and a new meta-
analysis have confirmed the benefits
of patent foramen ovale closure
where it is considered the likely cause
of stroke9

For stroke survivors with reduced strength in their
arms or legs, progressive resistance training should
be provided to improve strength

Updated

Based on a new systematic review,
there is now sufficient evidence to
specify the type of strength training
that is most efficacious 10
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Secondary prevention
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Rehabilitation
Weakness
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in Australia. Specifically, these systems include
the National Stroke Audit (detailed cross-sectional
audits of acute care and inpatient rehabilitation every
alternate year) and the Australian Stroke Clinical
Registry, whereby adherence to the national acute
care standards is continuously monitored, including
patient outcomes 90–180 days after stroke. These data
permit reliable assessment of practice change and
health outcomes over time to inform economic and
other impact assessments. However, preliminary
findings of the independent evaluation indicate
that end users of the living stroke management
guidelines report have increased trust in and
likelihood of accessing and following the guidelines
compared with the traditional, periodically updated
guideline model (Wiles L, Zurynski Y, Hibbert P, et
al. Living stroke guidelines evaluation. Australian
Institute of Health Innovation, 2021. Unpublished
report).
Importantly, living guidelines provide currency of
advice. The experience with stroke as well as other
guidelines3-5 demonstrates that the rigour of the
methods does not need to be compromised when
living modes are adopted. The GRADE method is as
appropriate for living guidelines as for traditional,
periodic guidelines. NHMRC support is also vital
in ensuring living guidelines continue to meet its
standards.
Sustainability remains the key challenge for the
living stroke guidelines. Collaboration with major
stroke guideline groups in Europe and North
America may improve guideline efficiency and
sustainability, but although discussions have
been undertaken, no formal projects have been
forthcoming as only a few groups currently use
the GRADE method. However, there has been
strong collaboration and sharing of knowledge and
experience with other national guideline groups as
part of the Australian Living Evidence Consortium
(https://livingevidence.org.au/). Compared with
the costs of updating the stroke guidelines every
five years, our initial experience indicates the living
model is likely to have similar overall costs, but with
the significant benefits of increased trust and use
from clinicians. Ongoing, secure funding for this
new model is now required for stroke along with
similar guidelines for other high burden diseases.

It is important to note that due to the living nature of
these guidelines, the information presented in this
article is correct at the time of writing but may have
been updated since.
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